Contact the EpiPen4Schools Programs

Phone: 973-845-7600
Fax: 973-718-4328
info@bioridgepharma.com

BioRidge Pharma facilitates the certification and fulfillment
of the EpiPen4Schools® orders.
The EpiPen4Schools® program helps improve access to epinephrine in the event a person experiences a life-threatening allergic reaction (anaphylaxis) in the school setting.
The program offers qualifying schools*:
  • Four free EpiPen® (epinephrine injection, USP) or EpiPen Jr® (epinephrine injection, USP) Auto-Injectors in the form of two EpiPen 2-Pak® cartons, two EpiPen Jr 2-Pak® cartons or one 2-Pak of each kind.
    Note: schools may receive the authorized generic versions of EpiPen and EpiPen Jr
  • Free replenishment product in the event that the free supply is used to respond to a life-threatening allergic reaction.
  • How to Use an EpiPen® (epinephrine injection, USP) Auto-Injector, containing instructions on how to use Mylan epinephrine auto-injectors.
  • EpiPen® Trainers, which contain no drug product or needle, to practice administering EpiPen® Auto-Injector.
CLICK HERE to start your order.
Epinephrine is the only first-line treatment for anaphylaxis. According to the food allergy guidelines developed by the National Institute of Allergy and Infectious Diseases, if experiencing anaphylaxis, a person should receive an intramuscular injection of epinephrine and seek immediate emergency medical care. Carrying an epinephrine auto-injector does not prevent patients from having an anaphylactic reaction; hence, patients must avoid their triggers at all times.
For more information on anaphylaxis or EpiPen® Auto-Injectors, visit epipen.com.

Did you know?

Anaphylaxis can develop and progress quickly, and children and adolescents are among the most at risk. A survey of more than 8,048 schools participating in EpiPen4Schools® revealed a total of 1,568 anaphylactic events among students and staff during the 2015-2016 school year. Also, the survey found:



  • More than one in four anaphylactic events occurred in the absence of an established or known allergic trigger
  • In 17% of reported anaphylaxis cases, the individual was not treated with epinephrine, the only first-line treatment for anaphylaxis
  • In those events where an epinephrine auto-injector was used, nearly 60% were treated with an EpiPen® Auto-Injector provided by the EpiPen4Schools® program
* A school will only receive epinephrine auto-injectors in accordance with all applicable laws. A school must submit a valid prescription in order to qualify for this program.